Avista Capital Partners and Hamilton Lane Announce Partnership in Cosette Pharmaceuticals
Avista Capital Partners and Hamilton Lane (Nasdaq: HLNE) have announced a partnership in Cosette Pharmaceuticals, a US-based specialty pharmaceutical company. Funds managed by Hamilton Lane have acquired a significant equity interest in Cosette from Avista and its co-investors. The partnership aims to accelerate innovation and growth for Cosette, which has shown robust EBITDA growth and free cash flow generation since Avista's initial investment in 2018.
Under new management, Cosette has successfully launched new products, expanded its portfolio through acquisitions and licensing deals, and diversified into branded products. The transaction enhances Cosette's balance sheet, enabling further investments in R&D and strategic acquisitions. Cosette also entered into new financing agreements with Hayfin Capital Management and a banking consortium.
- Hamilton Lane's investment provides additional capital for Cosette's growth
- Cosette has demonstrated robust EBITDA growth and free cash flow generation
- Successful diversification of portfolio with branded and innovative products
- New financing agreements to support future growth and acquisitions
- None.
Insights
Hamilton Lane's acquisition of a significant equity interest in Cosette Pharmaceuticals from Avista Capital Partners represents a notable development in the healthcare investment sector. This move suggests a robust confidence in Cosette’s future growth prospects, underpinned by its strategic focus on R&D and business development. The involvement of two major private equity firms will likely provide
From a financial perspective, the partnership strengthens Cosette’s balance sheet, enabling continued investments in R&D and strategic acquisitions. The new term loan financing with Hayfin Capital Management and the revolver provided by UBS Investment Bank and others further bolster Cosette's financial flexibility, ensuring that it has the necessary capital to drive sustained growth. Investors should closely monitor Cosette's financial performance in the coming quarters to gauge the effectiveness of these strategic initiatives.
While the infusion of capital and strategic oversight promises to enhance growth, potential risks include integration challenges with new acquisitions and the inherent uncertainties in pharmaceutical R&D. However, Cosette’s track record under Avista's initial investment, with successful product launches and market expansion, provides a solid foundation for optimism.
The partnership between Avista Capital Partners and Hamilton Lane is poised to significantly impact Cosette Pharmaceuticals' R&D capabilities and market expansion efforts. With a history of launching innovative products such as Vyleesi® and Intrarosa®, Cosette has demonstrated a strong commitment to developing and commercializing novel therapies. The additional financial resources and strategic support from Hamilton Lane are likely to accelerate these efforts.
Cosette's recent acquisition of Ambien® and Ambien CR® from Sanofi US highlights its strategy of expanding its branded product portfolio. This move not only enhances Cosette’s market presence but also diversifies its revenue streams, reducing reliance on any single product. The emphasis on both branded and patent-protected drugs positions Cosette well in the competitive pharmaceutical landscape.
However, it is important to consider the competitive pressures and regulatory hurdles that can affect new product launches and market penetration. The ability to successfully integrate new acquisitions and effectively manage R&D pipelines will be important in maintaining growth momentum. Overall, the strategic partnership and financial backing provide a promising outlook for Cosette’s continued innovation and market expansion.
Significantly Enhances Cosette's Ability to Drive Further Growth Through Investments in Business Development and R&D
Since Avista's initial investment in Cosette in December 2018, and under the leadership of a new executive management team, Cosette has successfully launched new and innovative products across its portfolio through a significant R&D effort as well as acquisitions and licensing deals which have expanded the company's presence across existing and new markets. This includes the recent acquisition of Ambien® and Ambien CR® in
Apurva Saraf, President and CEO of Cosette, stated, "This partnership is a testament to the remarkable transformation our business has achieved over the past four years, driven by an unwavering commitment to strategic business development and operational excellence. I am immensely proud of the entire Cosette team for their dedication in delivering this robust growth. We have successfully diversified our portfolio with branded products such as Clomid®, Ambien®, and Benicar®, along with innovative, patent-protected drugs like Vyleesi® and Intrarosa®. With our strong R&D and business development pipeline, we are well positioned to drive substantial growth in partnership with Avista and Hamilton Lane."
David Burgstahler, Managing Partner and CEO of Avista, added, "We value Avista's long-term relationship with Hamilton Lane and look forward to collaborating with them as a strategic partner to drive growth and value at Cosette. Our collective expertise will prove invaluable as Cosette evaluates larger M&A opportunities as part of the company's growth strategy."
Ken Binick, Managing Director and Co-Head of Direct Equity Investments at Hamilton Lane, said, "We are excited to advance our partnership with Avista and the Cosette management team. This is a compelling opportunity for us to invest in what we believe to be a high-quality asset and management team with a demonstrated track record of impressive growth and a clear path to further value creation."
This transaction enhances Cosette's balance sheet to continue to drive growth through investments in R&D and strategic acquisitions. The transaction will catalyze Cosette's ongoing mission to build a durable, high growth, branded pharmaceutical company in the near term.
In conjunction with the transaction, Cosette also entered into a new term loan financing with Hayfin Capital Management, and a new revolver provided by UBS Investment Bank, Capital One, National Association and Santander Corporate & Investment Bank, who acted as joint lead arrangers and joint bookrunners for the financing.
Ropes & Gray LLP advised Avista Capital Partners and Cosette Pharmaceuticals on this transaction and Debevoise & Plimpton LLP advised Hamilton Lane.
Forward-Looking Statements
Some of the statements in this release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Words such as "will", "expect", "believe", "estimate", "continue", "anticipate", "intend", "plan" and similar expressions are intended to identify these forward-looking statements. Forward-looking statements discuss management's current expectations and projections relating to our financial position, results of operations, plans, objectives, future performance and business. All forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different. You should evaluate all forward-looking statements in the context of the risks and uncertainties disclosed under the heading "Risk Factors" in Part I, Item 1A of Hamilton Lane's Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and subsequent reports filed from time to time with the Securities and Exchange Commission. The forward-looking statements included in this release are made only as of the date hereof. Hamilton Lane undertakes no obligation to update or revise any forward-looking statement as a result of new information or future events, except as otherwise required by law.
About Avista Capital Partners
Founded in 2005, Avista Capital is a leading
About Hamilton Lane
Hamilton Lane (Nasdaq: HLNE) is one of the largest private markets investment firms globally, providing innovative solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 700 professionals operating in offices throughout
About Cosette
Cosette Pharmaceuticals, Inc. ("Cosette") is a US-based, fully integrated pharmaceutical company with a fast-growing portfolio of branded pharmaceuticals consisting of products in women's health, cardiology and dermatology. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories. Cosette has corporate and manufacturing facilities in
Contacts:
For Avista Capital Partners:
Daniel Yunger / William Halliday
Kekst CNC
daniel.yunger@kekstcnc.com / william.halliday@kekstcnc.com
For Hamilton Lane:
Kate McGann
kmcgann@hamiltonlane.com
For Cosette Pharmaceuticals:
Lynn Munroe
Maracaibo Media Group
lynn@maracaibomedia.com
View original content:https://www.prnewswire.com/news-releases/avista-capital-partners-and-hamilton-lane-announce-partnership-in-cosette-pharmaceuticals-302198821.html
SOURCE Avista Capital Partners
FAQ
What is the significance of Hamilton Lane's investment in Cosette Pharmaceuticals?
How has Cosette Pharmaceuticals performed since Avista's initial investment in 2018?
What new financing arrangements has Cosette Pharmaceuticals secured?
How will the partnership between Avista Capital Partners and Hamilton Lane (HLNE) affect Cosette Pharmaceuticals?
